Cargando…
Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin)
Glioblastoma is a highly malignant brain tumor with no curative treatment options, and immune checkpoint blockade has not yet shown major impact. We hypothesized that drugs targeting mitosis might affect the tumor microenvironment and sensitize cancer cells to immunotherapy. We used 2 glioblastoma m...
Autores principales: | Genoud, Vassilis, Espinoza, Felipe I., Marinari, Eliana, Rochemont, Viviane, Dietrich, Pierre-Yves, McSheehy, Paul, Bachmann, Felix, Lane, Heidi A., Walker, Paul R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492343/ https://www.ncbi.nlm.nih.gov/pubmed/34403371 http://dx.doi.org/10.1172/jci.insight.142980 |
Ejemplares similares
-
Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours
por: Kristeleit, Rebecca, et al.
Publicado: (2020) -
EB1-dependent long survival of glioblastoma-grafted mice with the oral tubulin-binder BAL101553 is associated with inhibition of tumor angiogenesis
por: Bergès, Raphaël, et al.
Publicado: (2020) -
A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors
por: Joerger, Markus, et al.
Publicado: (2019) -
Concentrating on the mitotic spindle
por: Maddox, Paul S., et al.
Publicado: (2015) -
Bal
Publicado: (1965)